These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 28669041)

  • 1. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M; Matsumoto H; Mimura K; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
    Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
    Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study.
    Oshima Y; Kimoto K; Yoshida N; Fujisawa K; Sonoda S; Kubota T; Murata T; Sakamoto T; Yoshida S; Sonoda KH; Ishibashi T
    Ophthalmologica; 2017; 238(3):163-171. PubMed ID: 28697497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
    Takayama K; Kaneko H; Kataoka K; Ueno S; Chang-Hua P; Ito Y; Terasaki H
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):449-455. PubMed ID: 27538907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population.
    Wolff B; Vasseur V; Cahuzac A; Coscas F; Castelnovo L; Favard C; Michel G; Français C; Salomon L; Mauget-Faÿsse M
    Ophthalmologica; 2018; 240(4):208-212. PubMed ID: 29804123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.
    Matsumoto H; Mukai R; Kikuchi Y; Morimoto M; Akiyama H
    Jpn J Ophthalmol; 2020 Mar; 64(2):203-209. PubMed ID: 32016666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
    Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
    BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hosokawa MM; Ouchi C; Shiode Y; Kimura S; Matoba R; Morita T; Morizane Y
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3099-3107. PubMed ID: 38625447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
    Singh SR; Sahoo NK; Goud NR; Chhablani J
    Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.
    Sakai T; Kato N; Kubota M; Tsuneoka H
    Graefes Arch Clin Exp Ophthalmol; 2017 Aug; 255(8):1565-1571. PubMed ID: 28601912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience.
    Bansal A; Bhende M; Sharma T; Bhende P; Mukherjee S
    Indian J Ophthalmol; 2017 Aug; 65(8):758-760. PubMed ID: 28820169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study.
    Wong TY; Ogura Y; Lee WK; Iida T; Chen SJ; Mitchell P; Gemmy Cheung CM; Zhang Z; Leal S; Ishibashi T;
    Am J Ophthalmol; 2019 Aug; 204():80-89. PubMed ID: 30849345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
    Yoneda A; Wakiyama H; Kurihara J; Kitaoka T
    Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.